![](/img/cover-not-exists.png)
750 Preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development
S.D. Seiwert, S.W. Andrews, H. Tan, T. Wang, B. Marafino, R. Rieger, J. Pheneger, P.A. Lee, Y. Jiang, A.L. Kennedy, J. Ballard, H. Zhang, B. Bernat, K.R. Condrosld, C. Lemieux, B. Brandhuber, J.A. JosVolume:
44
Year:
2006
Language:
english
DOI:
10.1016/s0168-8278(06)80751-8
File:
PDF, 58 KB
english, 2006